Stephen D. Smith
Fred Hutch/University of Washington Cancer Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stephen D. Smith as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:55 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07910435 · Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan TrialUniversity of Washington · not yet recruiting · Mantle Cell Lymphoma · principal investigator
- Ph1/Ph2NCT05455697 · Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaUniversity of Washington · active not recruiting · Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma · principal investigator
- Ph2NCT05453396 · Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell MalignanciesUniversity of Washington · terminated · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma · principal investigator
- Ph2NCT04626791 · Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell LymphomaAcademic and Community Cancer Research United · active not recruiting · Mantle Cell Lymphoma
- Ph2NCT03401853 · Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell LymphomaUniversity of Washington · terminated · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 42 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Mapping the Human Connectome During Typical AgingU01AG052564 · NIA · WASHINGTON UNIVERSITY · fiscal years 2017 to 2019 · $4,132,562 awarded in 2019Same name and institution; not confirmed by an ID
- Mapping the Human Connectome During Typical DevelopmentU01MH109589 · NIMH · WASHINGTON UNIVERSITY · fiscal years 2016 to 2019 · $4,139,045 awarded in 2019Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2011 to 2026Named on NCT04626791
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:55 UTC. The ranking covers the 200 most relevant of 53 PubMed records, and a shared surname and initials can bring in a namesake. All 53 on PubMed
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.Lancet · 2018379 citationsRCR 12.8
- In-vitro maturation of human oocytes from regularly menstruating women may be successful without follicle stimulating hormone priming.Hum Reprod · 1999142 citationsRCR 4.9
- Reproducibility of anterior chamber angle measurements obtained with anterior segment optical coherence tomography.Invest Ophthalmol Vis Sci · 2007114 citationsRCR 5.0
- A long-term dose-response study of mitomycin in glaucoma filtration surgery.Arch Ophthalmol · 1997109 citationsRCR 5.2
- A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes.Diabetes Care · 2005104 citationsRCR 3.1
- Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.Nat Med · 2024103 citationsRCR 11.4
- Ahmed glaucoma valve implant vs trabeculectomy in the surgical treatment of glaucoma: a randomized clinical trial.Am J Ophthalmol · 200099 citationsRCR 5.1
- Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.Blood Adv · 202093 citationsRCR 4.0
- Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.Leukemia · 201988 citationsRCR 3.0
- Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.Br J Haematol · 202084 citationsRCR 3.3